Yungjin files 'KT&G101’ application for marketing approval with KFDA

Published: 2011-12-22 06:56:00

Updated: 2011-12-22 06:56:00

Biopid Co., a local biopharmaceutical company, said yesterday that its partner, Yungjin Pharma, has filed a marketing application for a new drug 'KT&G101’ for treatment of atopic dermatitis with the Korea Food and Drug Administration.

“KT&G101 possesses anti-inflammatory and related antinocice...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK